de en
  • Paion GmbH
  • Company

    About PAION

    1. History
    2. Management
    3. Supervisory Board

    Contact

    1. Germany
    2. UK

    Career

    1. What does PAIONeering mean to us?
    2. What PAIONeers can expect
    3. Job offers

    Information

    1. Events
    2. Information Request
  • Remimazolam

    Sedation & anesthesia market

    1. Overview
    2. Procedural Sedation (U.S.)
    3. General Anesthesia (Europe)
    4. ICU sedation

    Product Information

    1. About Remimazolam
    2. Clinical trials

    Medical Information

  • Pipeline

    Portfolio

    1. Overview
    2. Remimazolam
    3. GIAPREZA
    4. XERAVA

    Glossary

    1. A_Z
  • Partnering

    Strategy

    1. Partnering strategy
    2. Remimazolam strategy

    Licensing projects

    1. Remimazolam
    2. GIAPREZA
    3. XEVARA
  • Media and Investors

    At a glance

    1. General Information
    2. Contact

    Newsroom

    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company

    Information on shares

    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition

    Investorcenter

    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request

    Corporate Governance

    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board

    Annual general meeting

    2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
  • Scientific Hub
  • 12/18/2012

    PAION received milestone payment of USD 3 million from Ono Pharmaceutical due to enrolment of first patient into the Phase II/III study with Remimazolam in Japan

    • PDF

  • 11/05/2012

    PAION AG: New Supervisory Board Member appointed

    • PDF

  • 11/05/2012

    PAION's Partner ONO Pharmaceutical announced today initiation of a Phase II/III StudY with short-acting anaesthetic/sedative Remimazolam (ONO's Development code: ONO-2745) in Japan

    • PDF

  • 08/08/2012

    PAION AG reports financial results for the first half year 2012

    • PDF

  • 08/08/2012

    PAION realizes first step of strategic realignment: Purchase of Remifentanil distribution rights for Germany

    • PDF

  • 08/01/2012

    Article about Remimazolam has been chosen as article of the month by Anesthesia & Analgesia (A&A)

    • PDF

  • 07/18/2012

    PAION AG grants license to YICHANG Humanwell for Remimazolam in China

    • PDF

  • 07/09/2012

    Preclinical Efficacy of Solulin in radiation injury confirmed in US/german Research collaboration and published in “Nature Medicine“

    • PDF

  • 07/02/2012

    PAION Deutschland GmbH receives a Grant worth EUR 0.7 million from the Federal Ministry of Education and Reserach (BMBF) for research into the potential of thrombomodulin - mutants

    • PDF

  • 05/14/2012

    Results of Phase II Study of Remimazolam (ONO-2745/CNS 7056), a Short-acting General Anesthetic

    • PDF

  • 04/17/2012

    PAION receives Euro 2.1 Million through the sale of Desmoteplase by completion of data and know-how transfer from H. Lundbeck A/

    • PDF

  • 03/22/2012

    PAION signed exclusive option agreement with Yichang for Remimazolam in China

    • PDF

  • 03/14/2012

    PAION AG reports financial results for the full year 2011

    • PDF

  • 02/28/2012

    PAION Receives Euro 20 Million for Sale of Remaining Desmoteplase Rights to H. Lundbeck A/S

    • PDF

  • Media and Investors  » 
  • Newsroom  » 
  • Press Releases  » 
  • 2012
  • copyright © PAION AG I all rights reserved
  • Imprint
  • Privacy Statement
  • General Terms and Conditions
Paion

Martinstrasse 10-12 | 52062 Aachen | Deutschland

Tel.: +49 241 4453-0 | Fax.: +49 241 4453-100 | e-mail: info@paion.com

Company
  1. About PAION +
    1. History
    2. Management
    3. Supervisory Board
  2. Contact +
    1. Germany
    2. UK
  3. Career +
    1. What does PAIONeering mean to us?
    2. What PAIONeers can expect
    3. Job offers
  4. Information +
    1. Events
    2. Information Request
Remimazolam
  1. Sedation & anesthesia market +
    1. Overview
    2. Procedural Sedation (U.S.)
    3. General Anesthesia (Europe)
    4. ICU sedation
  2. Product Information +
    1. About Remimazolam
    2. Clinical trials
  3. Medical Information
Pipeline
  1. Portfolio +
    1. Overview
    2. Remimazolam
    3. GIAPREZA
    4. XERAVA
  2. Glossary +
    1. A_Z
Partnering
  1. Strategy +
    1. Partnering strategy
    2. Remimazolam strategy
  2. Licensing projects +
    1. Remimazolam
    2. GIAPREZA
    3. XEVARA
Media and Investors
  1. At a glance +
    1. General Information
    2. Contact
  2. Newsroom +
    1. Press Releases
    2. Ad-hoc Releases
    3. Directors' Dealings
    4. Holdings in company
  3. Information on shares +
    1. Chart & Fact sheet
    2. Analysts
    3. Capital actions
    4. Information on CeNeS Acquisition
  4. Investorcenter +
    1. Financial Reports
    2. Presentations
    3. Corporate calendar
    4. Information Request
  5. Corporate Governance +
    1. Declaration on Corporate Governance
    2. Articles of Association
    3. Declaration of Conformity
    4. Code of Conduct
    5. By-Laws Supervisory Board
  6. Annual general meeting +
    1. 2021
    2. 2020
    3. 2019
    4. 2018
    5. 2017
    6. 2016
    7. 2015
    8. 2014
    9. 2013
    10. 2012
    11. 2011
    12. 2010
Scientific Hub
Cookie Settings

This website uses cookies.

Some of them are essential and required for running the website. Others improve your user experience and may be activated or deactivated at your discretion.

Accept all Save
Privacy Statement Imprint